Person:
KARAÇAM, BÜŞRA

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
BÜŞRA
Last Name
KARAÇAM
Name
Email Address
Birth Date

Filters

2021 - 20245
Reset filters

Settings

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    PublicationMetadata only
    Glioma Hastalarının Tanısı ve Sağ Kalımında Hücre Dışı DNA ve Eksozomun Rolü
    (2022-06-21T00:00:00Z) Hatiboğlu, Mustafa Aziz; Karaçam, Büşra; HATİBOĞLU, MUSTAFA AZİZ; KARAÇAM, BÜŞRA
  • Thumbnail Image
    PublicationOpen Access
    Targeting Glioblastoma: The Current State of Different Therapeutic Approaches.
    (2021-01-13T00:00:00Z) Khan, Imran; Elbasan, Elif Burce; Mahfooz, Sadaf; Karacam, Busra; Oztanir, MUSTAFA NAMIK; Hatiboglu, Mustafa Aziz; KHAN, IMRAN; ELBASAN, ELİF BURÇE; KARAÇAM, BÜŞRA; ÖZTANIR, MUSTAFA NAMIK; HATİBOĞLU, MUSTAFA AZİZ
    Background: Glioma is the primary cancer of the central nervous system in adults. Among gliomas, glioblastoma is the most deadly and aggressive form, with an average life span of 1 to 2 years. Despite implementing the rigorous standard care involving maximal surgical removal followed by concomitant radiation and chemotherapy, the patient prognosis remains poor. Due to the infiltrative nature of glioblastoma, chemo- and radio-resistance behavior of these tumors and lack of potent chemotherapeutic drugs, treatment of glioblastoma is still a big challenge. Objective: The goal of the present review is to shed some light on the present state of novel strategies, including molecular therapies, immunotherapies, nanotechnology and combination therapies for patients with glioblastoma. Methods: Peer-reviewed literature was retrieved via Embase, Ovid, PubMed and Google Scholar till the year 2020. Conclusion: Insufficient effect of chemotherapies for glioblastoma is more likely because of different drug resistance mechanisms and intrinsically complex pathological characteristics. Therefore, more advancement in various therapeutic approaches such as antitumor immune response, targeting growth regulatory and drug resistance pathways, enhancing drug delivery and drug carrier systems are required in order to establish an effective treatment approach for patients with glioblastoma.
  • Thumbnail Image
    PublicationOpen Access
    Deciphering the role of autophagy in treatment of resistance mechanisms in glioblastoma
    (2021-02-01T00:00:00Z) KHAN, IMRAN; Baig, Mohammad Hassan; Mahfooz, Sadaf; Rahim, Moniba; KARAÇAM, BÜŞRA; ELBASAN, Elif Burçe; Ulasov, Ilya; Dong, Jae-June; HATİBOĞLU, MUSTAFA AZİZ; KHAN, IMRAN; KARAÇAM, BÜŞRA; ELBASAN, ELİF BURÇE; HATİBOĞLU, MUSTAFA AZİZ
    Autophagy is a process essential for cellular energy consumption, survival, and defense mechanisms. The role of autophagy in several types of human cancers has been explicitly explained; however, the underlying molecular mechanism of autophagy in glioblastoma remains ambiguous. Autophagy is thought to be a -double-edged sword-, and its effect on tumorigenesis varies with cell type. On the other hand, autophagy may play a significant role in the resistance mechanisms against various therapies. Therefore, it is of the utmost importance to gain insight into the molecular mechanisms deriving the autophagy-mediated therapeutic resistance and designing improved treatment strategies for glioblastoma. In this review, we discuss autophagy mechanisms, specifically its pro-survival and growth-suppressing mechanisms in glioblastomas. In addition, we try to shed some light on the autophagy-mediated activation of the cellular mechanisms supporting radioresistance and chemoresistance in glioblastoma. This review also highlights autophagy’s involvement in glioma stem cell behavior, underlining its role as a potential molecular target for therapeutic interventions.
  • No Thumbnail Available
    PublicationMetadata only
    Fare Serebral Glioblastoma Modelinde Hipofraksiyone Radyoterapinin İn vitro ve İn vivo Etkisinin Araştırılması
    (2023-06-19) Karaçam B.; Khan I.; Mahfooz S.; Akdur K.; Elbasan E. B.; Çoban G.; Hatiboğlu M. A.; KARAÇAM, BÜŞRA; ÇOBAN, GANİME; HATİBOĞLU, MUSTAFA AZİZ
  • No Thumbnail Available
    PublicationMetadata only
    Role of cell-free DNA and extracellular vesicles for diagnosis and surveillance in patients with glioma
    (2024-01-01) Karaçam B.; Elbasan E. B.; Khan I.; Akdur K.; Mahfooz S.; Merve C.; Yusuf C.; Hatiboğlu M. A.; KARAÇAM, BÜŞRA; HATİBOĞLU, MUSTAFA AZİZ
    Objectives: Liquid biopsy can be used to make the diagnosis, to screen treatment response, and to predict the prognosis. Extracellular vesicles (EVs) and cell-free DNA (cfDNA) sources are used as liquid biopsy biomarkers from body fluids such as serum, cerebrospinal fluid, urine, and mucosa. The purpose of this study was to investigate whether EVs and cfDNA are predictive for diagnosis and prognosis in patients with glioma. Methods: cfDNA and EVs levels were measured from 17 glioma patients at three different time intervals (before surgery, 10–14 days after surgery, and at the time of recurrence) and 7 healthy individuals. We investigated whether their level increased in glioma patients. Also, the correlation between clinical outcome and their levels was analyzed. Results: The mean serum cfDNA level in glioma patients was found to be higher compared to that in healthy controls. The difference between cfDNA level before surgery and that at 3 months follow-up was found to be statistically significant. Also, the mean serum EVs level in the glioma patients was found to be significantly higher compared to that in the control group. Discussion: Our results suggested that cfDNA and EVs could be used as diagnostic biomarkers in patients with glioma. cfDNA could be also a possible biomarker for the surveillance of glioma patients. Further studies are warranted to confirm our findings